

San Diego Vein Specialists, Inc. 765 Medical Center Ct. Suite 211 Chula Vista, CA, 91911 Ph: 619-271-7282 Fax 619-271-6161 Mehran Moussavian, D.O. Lisa Alvarez, PhD, FNP-BC

IAC INTERSOCIETAL ACCREDITATION COMMISSION

Lyndsay Silver FNP-C. MSN Email: <u>info@sdvein.com</u>

VARITHENA

Patient: RomellPamintuan Birthdate: 12/12/1966

Referring Physician: IyaboDaramola, MD

Provider: Mehran Moussavian, D.O.,FACC/Lyndsay Silver, NP

PCP LyndsaySilver,
Sonographer: AnnShaba,
Assistant: May, Yahaira

Date: 02/12/2021 09:32 AM

ICD10 Code(s):183.11VARICOSE VEINS RT LOW EXTREM INFLAM

CPT Code(s):36465Injection of non-compounded foam sclerosant w/ ultrasound compression maneuvers; single incompetent extremity truncal vein

Vitals:

H: 5 (ft) 5 (in).

Diagnosis:

Hyperlipidemia, unspecified (E78.5)

Asymptomatic varicose veins of bilateral lower extremities (183.93)

Chest pain, unspecified (R07.9)

Family history of ischemic heart disease and other diseases of the circulatory system (Z82.49)

Pain in leg, unspecified (M79.606)

Lack of physical exercise (Z72.3)

Personal history of nicotine dependence (Z87.891)

Venous insufficiency (chronic) (peripheral) (187.2)

Varicose veins of bilateral lower extremities with pain (183.813)

Procedure Introduction: Diagnosis: Symptomatic Reflux Right GSV

Operation/Procedure Performed: Varithena Right GSV distal calf to knee

Estimated Blood Loss: None

Diagnosis: Symptomatic Reflux Right GSV

Operation/Procedure Performed: Varithena Right GSV distal calf to knee

Estimated Blood Loss: None

Procedure Treatment: Patient was seen today for administration of Varithena® to the incompetent great saphenous vein/accessory saphenous veins/visible varicosities of the great saphenous vein (GSV system) below the knee of the right leg.

From Cardiovascular Institute of San 1.619.830.4179 Fri Feb 12 11:04:27 2021 MST Page 2 of 2 Page 2 of 2

DOB: 12/12/1966

Account #: 201712141228436 DOS:02/12/2021 09:32 AM

The patient was given an explanation of the protocol for the administration of Varithena. We went over the potential adverse reactions and what to do in the event that one or more occur. After agreement, the patient was positioned on the examination table to examine and measure the veins requiring treatment -the [GSV/accessory saphenous veins/visible varicosities of the GSV system] 26 cm below the right knee. Lidocaine was administered locally, the vein was then cannulated using ultrasound guidance, and venous access was confirmed. Using aseptic technique and following manufacturer's guidance on product use 2 mL of Varithena was withdrawn from the drug canister using the Varithena® Transfer Unit to a sterile syringe, injected into the cannula slowly, and monitored using duplex ultrasound. Venospasm of the treated vein was confirmed using ultrasound. The catheter was removed from the treatment site and a compression bandage and stocking were applied to the treatment area. The patient was monitored and observed for anaphylactic reaction without incident while walking in the office for 10 minutes and instructed to schedule a follow up visit with in the next 1 to 2 weeks to re-examine the treatment site, using duplex ultrasound, and address potential additional treatment, if necessary. The patient was advised to keep post treatment bandages dry and in place for 48 hours, avoid heavy exercise for one week, wear compression stockings on the treated leg continuously for two weeks, avoid extended periods of inactivity, walk daily for 10 minutes over the next month.

Patient was seen today for administration of Varithena® to the incompetent great saphenous vein/accessory saphenous veins/visible varicosities of the great saphenous vein (GSV system) below the knee of the right leg.

The patient was given an explanation of the protocol for the administration of Varithena. We went over the potential adverse reactions and what to do in the event that one or more occur. After agreement, the patient was positioned on the examination table to examine and measure the veins requiring treatment -the [GSV/accessory saphenous veins/visible varicosities of the GSV system] 26 cm below the right knee. Lidocaine was administered locally, the vein was then cannulated using ultrasound guidance, and venous access was confirmed. Using aseptic technique and following manufacturer's guidance on product use 2 mL of Varithena was withdrawn from the drug canister using the Varithena® Transfer Unit to a sterile syringe, injected into the cannula slowly, and monitored using duplex ultrasound. Venospasm of the treated vein was confirmed using ultrasound. The catheter was removed from the treatment site and a compression bandage and stocking were applied to the treatment area. The patient was monitored and observed for anaphylactic reaction without incident while walking in the office for 10 minutes and instructed to schedule a follow up visit with in the next 1 to 2 weeks to re-examine the treatment site, using duplex ultrasound, and address potential additional treatment, if necessary. The patient was advised to keep post treatment bandages dry and in place for 48 hours, avoid heavy exercise for one week, wear compression stockings on the treated leg continuously for two weeks, avoid extended periods of inactivity, walk daily for 10 minutes over the next month.

Electronically signed by Lyndsay Silver, Mehran Moussavian, D.O., FACC/NP on 2/12/2021 10:02:33 AM.

